News: Roche Holding AG (ROG.VX)

ROG.VX on Virt-X Level 1

267.70CHF
29 Aug 2014
Price Change (% chg)

CHF0.60 (+0.22%)
Prev Close
CHF267.10
Open
CHF267.60
Day's High
CHF268.60
Day's Low
CHF265.70
Volume
975,342
Avg. Vol
1,040,432
52-wk High
CHF274.80
52-wk Low
CHF231.20

Search Stocks
Select another date:

Thu, Aug 28 2014

Fitch Affirms Roche at 'AA'/Stable on InterMune Buy

(The following statement was released by the rating agency) LONDON, August 28 (Fitch) Fitch Ratings has affirmed Switzerland-based healthcare company Roche's Long-term Issuer Default Rating (IDR) and senior unsecured rating at 'AA'. The Short-term IDR has been affirmed at 'F1+'. The Outlook is 'Stable'. A full list of rating actions is available at the end of this commentary. The rating affirmation follows Roche's proposed tender offer to acquire 100% of US-based biotech company InterMune

InterMune drug may offer big upside to Roche if aimed at liver

- Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.

Roche to buy U.S. biotech firm InterMune for $8.3 billion

LONDON/ZURICH - Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, helping the world's leading maker of cancer drugs expand into the treatment of rare or incurable diseases. | Video

US STOCKS-Futures point to higher open; S&P 500 near record

* Futures up: Dow 58 pts, S&P 7.75 pts, Nasdaq 17.5 pts (Updates prices)

US STOCKS-Futures rise on hopes for ECB action, merger activity

NEW YORK, Aug 25 - U.S. stock index futures were modestly higher on Monday, indicating the S&P 500 would open near record levels, amid corporate merger activity and as hopes grew for more monetary stimulus in European markets.

UPDATE 4-Roche to buy U.S. biotech firm InterMune for $8.3 bln

* Consensus 2019 sales for InterMune lung drug $1.04 bln (Adds additional analyst comment, shares)

BRIEF-Roche shares rise 0.4 pct after announcing InterMune deal

Aug 25 - Roche Holding AG : * Shares rise 0.4 percent after announcing purchase of U.S. biotech firm

RPT-Chugai down 9 pct after report Roche decided against buyout

TOKYO, Aug 25 - Shares of Chugai Pharmaceutical Co Ltd plunged 9 percent early on Monday after Bloomberg said Roche Holding AG had decided against bidding for the nearly 40 percent of the Japanese drugmaker that it does not already own.

Chugai down 9 pct after report Roche decided against buyout

TOKYO, Aug 25 - Shares of Chugai Pharmaceutical Co Ltd plunged 9 percent early on Monday after Bloomberg said Roche Holding AG had decided against bidding for the nearly 40 percent of the Japanese drugmaker that it does not already own.

Roche to buy U.S. biotech firm InterMune for $8.3 billion

LONDON/ZURICH - Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.

Select another date:
Search Stocks